I TUOI DATI
I TUOI ORDINI
N. prodotti: 0
Totale ordine: € 0,00
I TUOI ABBONAMENTI
I TUOI ARTICOLI
THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Rivista di Medicina Nucleare e Imaging Molecolare
A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413
ORIGINAL ARTICLES NEUROPHARMACOLOGY
The Quarterly Journal of Nuclear Medicine 1998 September;42(3):151-7
What are we measuring with PET?
Morgan A. E., Brodie J. D.*, Dewey S. L.
From the Chemistry Department Brookhaven National Laboratory, Upton, New York, USA
* Psychiatry Department New York University School of Medicine, New York, USA
Positron emission tomography is a medical imaging technique that provides unique information concerning many biochemical mechanisms underlying normal physiologic function. With respect to the central nervous system (CNS), selective radiolabeled compounds targeted at specific neurotransmitter receptor systems reveal information not only concerning receptor distribution and enzymatic activity but neurotransmitter concentrations as well. Recent advances in our understanding of these systems may be utilized to further understand changes in brain biochemistry that either result from or produce symptomatology associated with many CNS disease states. The ability to measure interactions between neurotransmitter systems in the human brain may also add to our knowledge of drug side effects and disease progression. While many CNS diseases have been defined as “neurotransmitter-specific” in nature, scientific data now suggests that changes in multiple neurotransmitter systems are evident in the brains of patients suffering from these classically described diseases. PET is a powerful tool that can be used to examine many of these changes in the living human brain.